Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse
TIPA
1 other identifier
interventional
100
0 countries
N/A
Brief Summary
The main of this study is to assess the feasibility of a patients follow-up visit receiving trastuzumab subcutaneous by Advanced Practice Nurse.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2016
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2016
CompletedFirst Submitted
Initial submission to the registry
February 8, 2016
CompletedFirst Posted
Study publicly available on registry
February 22, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedFebruary 22, 2016
February 1, 2016
1 year
February 8, 2016
February 16, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of consultation requiring a medical advice between IPA and oncologist
Estimate the correlation between the IPA and the oncologist about whether or not a medical opinion during the consultation
1 year
Secondary Outcomes (2)
Percentage of consultations delegated to the IPA
1 year
Physician satisfaction questionnaire
1 year
Study Arms (1)
consultation by Advanced Practice Nurse.
EXPERIMENTALDuring consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.
Interventions
Eligibility Criteria
You may qualify if:
- Patient care at the Cancer Institute Lucien Neuwirth
- Patient aged over 18 years
- Patient with breast cancer overexpressing HER2 adjuvant
- Patient having finished their chemotherapy treatment with IV followed the oncologist day hospital
- Patient under Trastzumab subcutaneously
- Patient affiliated or entitled to a social security scheme (mandatory requirement for all studies)
You may not qualify if:
- Refusal to participate, most patient protected under guardianship.
- Patient in inability to understand the course of the study
- Patient with documented history of cognitive or psychiatric disorders.
- Patients pregnant or lactating
- Patients under guardianship or curatorship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 8, 2016
First Posted
February 22, 2016
Study Start
February 1, 2016
Primary Completion
February 1, 2017
Study Completion
December 1, 2017
Last Updated
February 22, 2016
Record last verified: 2016-02